---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-22-012165"
form_type: "8-K"
ticker: "COLL"
cik: "0001267565"
company_name: "COLLEGIUM PHARMACEUTICAL, INC"
filed_at: "2022-08-04T23:59:59+00:00"
generated_at: "2026-06-24T03:46:10.488619+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Collegium Q2 revenue $123.5M record, raises FY Adj EBITDA guidance to $245-255M

## Summary
- Q2 net product revenue $123.5M (record), up from $82.9M YoY.
- GAAP net loss $5.2M ($0.15 loss per share) vs $72.8M income in prior year (included tax benefit).
- Adjusted EBITDA $71.2M, up from $40.1M YoY; full-year Adj EBITDA guidance raised to $245-255M.
- BDSI integration complete; on track to exceed targeted run-rate synergies of at least $75M.
- Opioid lawsuits resolved via master settlement agreement covering 27 pending cases.

## SEC filing metadata
- accession: 0001558370-22-012165
- form_type: 8-K
- ticker: COLL
- cik: 0001267565
- company_name: COLLEGIUM PHARMACEUTICAL, INC
- filed_at: 2022-08-04T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1267565/000155837022012165/0001558370-22-012165-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1267565/000155837022012165/coll-20220804x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-22-012165
- JSON: https://secwatch.observer/filing/0001558370-22-012165.json
- Plain text: https://secwatch.observer/filing/0001558370-22-012165.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.